Wexford Capital LP Buys New Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Wexford Capital LP purchased a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 14,000 shares of the biopharmaceutical company's stock, valued at approximately $421,000.

A number of other institutional investors have also recently made changes to their positions in TGTX. Clearbridge Investments LLC acquired a new stake in shares of TG Therapeutics in the fourth quarter worth approximately $55,237,000. Raymond James Financial Inc. acquired a new stake in shares of TG Therapeutics in the fourth quarter worth approximately $14,508,000. Braun Stacey Associates Inc. acquired a new stake in shares of TG Therapeutics in the fourth quarter worth approximately $13,328,000. Norges Bank acquired a new stake in shares of TG Therapeutics in the fourth quarter worth approximately $12,085,000. Finally, Penn Capital Management Company LLC acquired a new position in TG Therapeutics during the fourth quarter worth $10,577,000. 58.58% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Wall Street Zen raised TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $40.80.

TG Therapeutics Stock Up 1.0%

NASDAQ TGTX traded up $0.33 during trading hours on Friday, hitting $34.57. 1,042,767 shares of the company were exchanged, compared to its average volume of 2,983,166. The company has a 50 day moving average of $38.13 and a two-hundred day moving average of $34.22. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 52-week low of $15.16 and a 52-week high of $46.48. The firm has a market cap of $5.49 billion, a price-to-earnings ratio of -345.67 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. During the same quarter last year, the company earned ($0.07) EPS. TG Therapeutics's revenue for the quarter was up 90.4% compared to the same quarter last year. Equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.